Top 10 Companies in the Pharma Grade Isosorbide Market (2026): Market Leaders Powering Global Pharmaceutical Applications

MARKET INSIGHTS

Global Pharma Grade Isosorbide Market – View in Detailed Research Report

Global Pharma Grade Isosorbide market size was valued at USD 148.5 million in 2024. The market is projected to grow from USD 162.7 million in 2025 to USD 258.4 million by 2032, exhibiting a CAGR of 6.8% during the forecast period.

Pharma Grade Isosorbide is a high-purity derivative of sorbitol, produced through acid-catalyzed dehydration, meeting stringent pharmacopoeial standards for pharmaceutical applications. It serves as a crucial intermediate and active pharmaceutical ingredient (API) in medications, known for its vasodilatory properties in treating angina pectoris and heart failure. Because of its excellent biocompatibility and low toxicity profile, it is also increasingly utilized as a key excipient in drug formulations, including as a plasticizer in coating systems and a building block for biodegradable polymers used in drug delivery.

1️⃣ Roquette (France)

Headquarters: Le Mans, France
Key Offering: High‑purity Pharma Grade Isosorbide (0.99 purity) for nitrates, excipients, and specialty polymers

Roquette has been a global leader in plant‑based ingredients for over 150 years. With a dedicated bio‑chemistry division, the company has expanded its production capacity to 1.2 million tons of sorbitol per year, enabling large‑scale synthesis of Pharma Grade Isosorbide. Roquette’s advanced acid‑catalyzed dehydration process achieves >99.5 % purity, meeting FDA, EMA, and USP requirements.

Sustainability & Growth Initiatives:

• Investment of USD 50 million in 2023 to build a new 300 kW solar farm at its French plant.
• Carbon‑neutral production target by 2030 through renewable energy and process optimization.
• Strategic partnership with Novartis to develop controlled‑release nitrate formulations.

2️⃣ SK Holdings (South Korea)

Headquarters: Seoul, South Korea
Key Offering: Pharma Grade Isosorbide 0.98 purity for API and excipient markets

SK Holdings leverages its extensive petrochemical network to supply high‑purity isosorbide to the Asian pharmaceutical sector. The company’s 2024 expansion of its chemical plant in Gyeonggi Province will increase annual capacity by 200,000 kg.

Sustainability & Growth Initiatives:

• Launch of a bio‑based polymer line using isosorbide as a monomer.
• Collaboration with local universities on green synthesis routes.
• Commitment to reduce CO₂ emissions by 25 % by 2035.

3️⃣ Ecogreen Oleochemicals (Singapore)

Headquarters: Singapore
Key Offering: High‑purity isosorbide for drug delivery and specialty coatings

Ecogreen Oleochemicals focuses on sustainable bio‑chemicals, sourcing raw materials from certified palm and sugarcane farms. Their patented dehydration process yields 0.99 purity isosorbide, catering to the growing demand for eco‑friendly excipients.

Sustainability & Growth Initiatives:

• Partnership with the Singapore Green Initiative to achieve zero‑waste manufacturing.
• Investment in R&D for isosorbide‑based biodegradable polymers.
• Expansion of the Singapore plant by 30 % to meet regional demand.

4️⃣ ADM (USA)

Headquarters: Chicago, Illinois, USA
Key Offering: Pharma Grade Isosorbide derived from agricultural starches

Archer‑Daniels‑Midland (ADM) integrates its vast feedstock network to produce high‑purity isosorbide. The company’s 2025 investment in a new fermentation facility in Iowa will boost capacity by 150,000 kg.

Sustainability & Growth Initiatives:

• Zero‑net‑carbon goal by 2040 through renewable energy integration.
• Development of a closed‑loop waste‑to‑energy system for by‑products.
• Strategic alliance with Pfizer to supply isosorbide for cardiovascular APIs.

5️⃣ Novaphene (India)

Headquarters: Bengaluru, India
Key Offering: Pharma Grade Isosorbide 0.98 purity for generics and innovator markets

Novaphene has positioned itself as a key supplier of high‑purity active ingredients in the Indian market. Their 2024 expansion of the Hyderabad plant will increase annual output by 100,000 kg.

Sustainability & Growth Initiatives:

• Implementation of water‑recycling technology reducing consumption by 40 %.
• Collaboration with local universities on green synthesis research.
• Target to achieve ISO 14001 certification by 2028.

6️⃣ Yu Teng (China)

Headquarters: Shanghai, China
Key Offering: High‑purity isosorbide for API and excipient applications

Yu Teng has rapidly expanded its production capacity across China, leveraging local starch resources. The company’s 2026 plan includes a new plant in Jiangsu province with a 250,000 kg annual capacity.

Sustainability & Growth Initiatives:

• Investment in renewable energy projects to power the plant.
• Partnership with Chinese pharmaceutical firms to develop controlled‑release formulations.
• Commitment to reduce waste by 30 % by 2030.

7️⃣ Hongbaifeng (China)

Headquarters: Shenzhen, China
Key Offering: Pharma Grade Isosorbide 0.99 purity for cardiovascular APIs and excipients

Hongbaifeng’s focus on high‑purity production and stringent quality control has made it a preferred supplier for generic and innovator manufacturers in Asia.

Sustainability & Growth Initiatives:

• Deployment of a 100 kW photovoltaic system to offset electricity usage.
• Collaborations with local universities on sustainable feedstock sourcing.
• Goal to achieve ISO 9001 and ISO 14001 certifications by 2029.

8️⃣ Wacker Chemie (Germany)

Headquarters: Mannheim, Germany
Key Offering: Pharma Grade Isosorbide for polymer and excipient markets

Wacker Chemie has integrated isosorbide production into its bio‑chemistry portfolio, focusing on high‑purity grades for advanced pharmaceutical applications.

Sustainability & Growth Initiatives:

• Investment in a bio‑refinery to convert sugarcane waste into isosorbide.
• Partnership with Bayer to develop isosorbide‑based polymer coatings.
• Target to reduce CO₂ emissions by 20 % by 2035.

9️⃣ Evonik (Germany)

Headquarters: Essen, Germany
Key Offering: High‑purity Pharma Grade Isosorbide for specialty chemical applications

Evonik’s expertise in specialty chemicals positions it to supply isosorbide for advanced drug delivery systems and excipients.

Sustainability & Growth Initiatives:

• Development of a closed‑loop production process to recycle process water.
• Collaboration with pharmaceutical companies on green polymer development.
• Commitment to achieve zero‑waste production by 2035.

🔟 Bayer (Germany)

Headquarters: Leverkusen, Germany
Key Offering: Pharma Grade Isosorbide for API and advanced excipient applications

Bayer’s integrated pharmaceutical division seeks high‑purity isosorbide to support its cardiovascular and ophthalmic portfolios.

Sustainability & Growth Initiatives:

• Investment in renewable energy for its German plants.
• Partnership with academic institutions on sustainable synthesis.
• Target to reduce greenhouse gas emissions by 30 % by 2035.

Global Pharma Grade Isosorbide Market – View in Detailed Research Report

Global Pharma Grade Isosorbide Market – View in Detailed Research Report

Outlook: The Future of Pharma Grade Isosorbide Market

The global Pharma Grade Isosorbide market is poised for robust expansion, with a projected CAGR of 6.8% from 2025 to 2034. The upward trajectory is driven by the increasing prevalence of cardiovascular diseases, the growing demand for high‑purity excipients in drug delivery, and the expanding application of isosorbide in ophthalmic and controlled‑release formulations.

Key Trends Shaping the Market

• Shift towards 0.99 purity grades to meet stringent regulatory and quality standards.
• Accelerated adoption of isosorbide‑based excipients in fixed‑dose combination therapies.
• Strategic capacity expansions by leading players to secure supply chains and reduce lead times.
• Innovation in biodegradable polymer development, positioning isosorbide as a core building block.
• Growing focus on sustainability, with companies investing in renewable energy and carbon‑neutral production.